...
首页> 外文期刊>Wilderness & environmental medicine >Management of high altitude pulmonary edema in the himalaya: A review of 56 cases presenting at pheriche medical aid post (4240 m)
【24h】

Management of high altitude pulmonary edema in the himalaya: A review of 56 cases presenting at pheriche medical aid post (4240 m)

机译:喜马拉雅山高海拔肺水肿的处理:复查在pheriche医疗救助站(4240 m)的56例病例

获取原文
获取原文并翻译 | 示例

摘要

Objective: The purpose of this study was to review the patient characteristics and management of 56 cases of high altitude pulmonary edema at the Pheriche Himalayan Rescue Association Medical Aid Post, and to measure the use of medications in addition to descent and oxygen. Methods: In a retrospective case series, we reviewed all patients diagnosed clinically with high altitude pulmonary edema during the 2010 Spring and Fall seasons. Nationality, altitude at onset of symptoms, physical examination findings, therapies administered, and evacuation methods were evaluated. Results: Of all patients, 23% were Nepalese, with no difference in clinical features compared with non-Nepalese patients; 28% of all patients were also suspected of having high altitude cerebral edema. Symptoms developed in 91% of all patients at an altitude higher than the aid post (median altitude of onset of 4834 m); 83% received oxygen therapy, and 87% received nifedipine, 44% sildenafil, 32% dexamethasone, and 39% acetazolamide. Patients who were administered sildenafil, dexamethasone, or acetazolamide had presented with significantly lower initial oxygen saturations (P ??.05). After treatment, 93% of all patients descended; 38% descended on foot without a supply of oxygen. Conclusions: A significant number of patients presenting to the Pheriche medical aid post with high altitude pulmonary edema were given dexamethasone, sildenafil, or acetazolamide in addition to oxygen, nifedipine, and descent. This finding may be related to perceived severity of illness and evacuation limitations. Although no adverse effects were observed, the use of multiple medications is not supported by current evidence and should not be widely adopted without further study. ? 2013 Wilderness Medical Society.
机译:目的:本研究的目的是回顾Pheriche喜马拉雅救援协会医疗救助站的56例高海拔肺水肿的患者特征和治疗方法,并测量除血统和氧气外的药物使用情况。方法:在回顾性病例系列中,我们回顾了2010年春秋季节期间所有临床诊断为高海拔肺水肿的患者。评估了国籍,症状发作时的海拔高度,体格检查结果,所用疗法和疏散方法。结果:在所有患者中,尼泊尔人占23%,与非尼泊尔人相比,临床特征无差异;所有患者中有28%还被怀疑患有高原脑水肿。 91%的患者在高于急救站的高度出现症状(发作的中位数海拔4834 m); 83%的患者接受了氧疗,87%的患者接受了硝苯地平,44%的西地那非,32%的地塞米松和39%的乙酰唑胺。服用西地那非,地塞米松或乙酰唑胺的患者的初始氧饱和度显着降低(P <0.05)。治疗后,所有患者中有93%下降。 38%的人步行时没有氧气供应。结论:除氧气,硝苯地平和血统下降外,许多在Pheriche医院就诊的高海拔肺水肿患者还接受了地塞米松,西地那非或乙酰唑胺治疗。该发现可能与疾病的严重程度和疏散限制有关。尽管未观察到不良反应,但当前证据不支持使用多种药物,未经进一步研究,不应广泛采用。 ? 2013荒野医学协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号